Pds biotech completes $35 million financing agreement led by horizon technology finance

Florham park, n.j., aug. 24, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary versamune® and infectimune™ t cell activating technologies, today announced that it has entered into a debt financing agreement led by horizon technology finance corporation (nasdaq: hrzn) (“horizon”) to provide up to a $35.0 million term loan.
PDSB Ratings Summary
PDSB Quant Ranking